1. Immune Biomarkers on the Radar—Comprehensive “Immunograms” for Multimodal Treatment Prediction 
Johan Botling, MD, PhD, Martin Sandelin, MD, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 5, Pages (May 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Representative immunograms of T-cell–poor (upper panel) and T-cell–rich (lower panel) NSCLC cases. The 8 axes in the radar plots illustrate the range of biomarker scores obtained for eight different immune parameters related to T-cell–mediated antitumor activities, as explained in the main text. The T-cell–poor case largely lacks immune suppressive traits (axes 6 to 8) but scores low on tumor antigen expression (axis 2), dendritic cell activation (axis 3), T-cell trafficking (axis 4), and antigen-presenting capabilities (axis 5). This patient could hypothetically benefit from candidate immune-stimulatory agents as indicated. The T-cell–rich case has an opposite pattern influenced by signs of inhibitory activities (axes 6 and 8) in addition to checkpoint molecule expression (axis 7). This patient might need treatments, in addition to programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1 inhibition), that counteract other immune-suppressive mechanisms. CTLA4, cytotoxic T-lymphocyte antigen 4; IFN-α, interferon-α; CAR-T, chimeric antigen receptor T; Treg, regulatory T cell; MDSC, myeloid-derived suppressor cell; IDO1, indoleamine 2,3-dioxygenase 1.
(Modified with permission from Karasaki et al.6)
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions